Oncotarget

Research Papers:

Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model

Yuan Gu, Christina Körbel, Claudia Scheuer, Anca Nenicu, Michael D. Menger and Matthias W. Laschke _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:5258-5272. https://doi.org/10.18632/oncotarget.6676

Metrics: PDF 1522 views  |   HTML 1622 views  |   ?  


Abstract

Yuan Gu1, Christina Körbel1, Claudia Scheuer1, Anca Nenicu1, Michael D. Menger1, Matthias W. Laschke1

1Institute for Clinical & Experimental Surgery, Saarland University, Homburg/Saar 66421, Germany

Correspondence to:

Matthias W. Laschke, e-mail: matthias.laschke@uks.eu

Keywords: tubeimoside-1, angiogenesis, tumor, VEGFR2, Tie2

Received: September 03, 2015     Accepted: December 07, 2015     Published: December 19, 2015

ABSTRACT

Tubeimoside-1 (TBMS1) is a potent anti-tumor phytochemical. Its functional and molecular mode of action, however, remains elusive so far. Since angiogenesis is essential for tumor progression and metastasis, we herein investigated the anti-angiogenic effects of the compound. In a non-small cell lung cancer (NSCLC) xenograft model we found that treatment of CD1 nu/nu mice with TBMS1 (5 mg/kg) significantly suppressed the growth and vascularization of NCI-H460 flank tumors. Moreover, TBMS1 dose-dependently reduced vascular sprouting in a rat aortic ring assay. In vitro, TBMS1 induced endothelial cell apoptosis without decreasing the viability of NSCLC tumor cells and inhibited the migration of endothelial cells by disturbing their actin filament organization. TBMS1 further stimulated the proteasomal degradation of vascular endothelial growth factor receptor-2 (VEGFR2) and Tie2 in endothelial cells, which down-regulated AKT/mTOR signaling. These findings indicate that TBMS1 represents a novel phytochemical for anti-angiogenic treatment of cancer and other angiogenesis-related diseases.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6676